| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $793,075 | 7 | 100 |
| Bizily Scott | Chief Legal Officer | 0 | $0 | 5 | $203,765 | $-203,765 |
| Kirn David | Chief Executive Officer | 0 | $0 | 2 | $589,310 | $-589,310 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Over the last 12 months, insiders at 4D Molecular Therapeutics, Inc. have bought $0 and sold $793,075 worth of 4D Molecular Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at 4D Molecular Therapeutics, Inc. have bought $44.27M and sold $5.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 850,000 shares for transaction amount of $13.6M was made by VIKING GLOBAL INVESTORS LP (10 percent owner) on 2023‑05‑09.
| 2024-09-16 | Sale | Bizily Scott | Chief Legal Officer | 500 0.001% | $16.33 | $8,165 | -70.87% | |
| 2024-08-19 | Sale | Bizily Scott | Chief Legal Officer | 500 0.001% | $15.00 | $7,500 | -62.37% | |
| 2024-07-16 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0044% | $27.11 | $47,443 | -77.83% | |
| 2024-07-11 | Sale | Bizily Scott | Chief Legal Officer | 1,996 0.0046% | $25.00 | $49,900 | -76.85% | |
| 2024-07-10 | Sale | Kirn David | Chief Executive Officer | 12,923 0.0268% | $22.49 | $290,598 | -74.28% | |
| 2024-07-01 | Sale | Bizily Scott | Chief Legal Officer | 4,248 0.0084% | $21.36 | $90,758 | -70.41% | |
| 2024-06-24 | Sale | Kirn David | Chief Executive Officer | 12,930 0.0248% | $23.10 | $298,711 | -72.65% | |
| 2024-06-17 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0034% | $23.71 | $41,494 | -72.65% | |
| 2024-05-16 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0034% | $25.45 | $44,541 | -68.47% | |
| 2024-04-16 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0034% | $25.74 | $45,045 | -66.99% | |
| 2024-04-01 | Sale | Bizily Scott | Chief Legal Officer | 8,153 0.0173% | $31.78 | $259,102 | -63.98% | |
| 2024-03-27 | Sale | Bizily Scott | Chief Legal Officer | 5,833 0.0114% | $35.04 | $204,410 | -69.00% | |
| 2024-03-18 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0035% | $31.27 | $54,723 | -53.55% | |
| 2024-02-27 | Sale | Bizily Scott | Chief Legal Officer | 1,909 0.0039% | $30.00 | $57,270 | -49.41% | |
| 2024-02-16 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0036% | $27.67 | $48,423 | -43.14% | |
| 2024-02-08 | Sale | Kirn David | Chief Executive Officer | 92,001 0.3275% | $27.13 | $2.5M | -41.34% | |
| 2024-02-08 | Sale | Bizily Scott | Chief Legal Officer | 1,996 0.0072% | $27.50 | $54,890 | -41.34% | |
| 2024-02-05 | Sale | Kim Robert Young | Chief Medical Officer | 6,552 0.0258% | $30.05 | $196,888 | -50.17% | |
| 2024-01-23 | Sale | Kirn David | Chief Executive Officer | 5,696 0.0133% | $18.41 | $104,851 | -6.55% | |
| 2024-01-05 | Sale | Kirn David | Chief Executive Officer | 28,237 0.0659% | $19.57 | $552,478 | -7.55% |
| Kirn David | Chief Executive Officer | 1059153 2.2864% | $4.33M | 0 | 14 | |
| Bizily Scott | Chief Legal Officer | 6781 0.0146% | $27,734.29 | 0 | 19 | |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 4247914 9.1699% | $17.37M | 2 | 1 | <0.0001% |
| YAO TONY DUNG LING | director | 1060880 2.2901% | $4.34M | 1 | 0 | <0.0001% |
| SCHAFFER DAVID | director | 901215 1.9454% | $3.69M | 0 | 7 | |
| MILLIGAN JOHN F | director | 100000 0.2159% | $409,000.00 | 1 | 0 | <0.0001% |
| Kamal Fariborz | See Remarks | 4347 0.0094% | $17,779.23 | 1 | 0 | <0.0001% |
| Kim Robert Young | Chief Medical Officer | 1043 0.0023% | $4,265.87 | 0 | 1 | |
| Chacko Jacob | director | 0 0% | $0 | 0 | 1 |
$8,253,997 | 122 | -53.40% | $188.56M | |
$7,224,762 | 91 | -8.21% | $168.19M | |
$87,639,490 | 62 | 18.37% | $189.87M | |
$613,304,943 | 46 | 11.85% | $186.26M | |
$17,983,739 | 41 | 102.87% | $200.91M | |
$2,545,071 | 34 | 16.59% | $194.69M | |
$79,019,806 | 27 | 7.24% | $175.44M | |
$91,870,774 | 13 | 3.64% | $206.94M | |
$1,229,070 | 10 | 23.53% | $188.67M | |
$55,069,530 | 9 | 25.25% | $203.81M | |
$6,593,243 | 8 | 12.72% | $196.73M | |
$145,296,407 | 8 | -0.98% | $168.22M | |
$12,047,724 | 8 | 209.62% | $201.8M | |
$5,905,507 | 7 | 2.69% | $199.67M | |
$17,675,244 | 7 | 92.20% | $168.77M | |
$45,000,000 | 6 | -31.22% | $187.48M | |
4D Molecular Therapeutics, Inc. (FDMT) | $88,549,962 | 5 | -16.91% | $189.47M |
$40,000,000 | 3 | -16.24% | $168.65M | |
$9,999,990 | 1 | 32.51% | $200.59M |
| Increased Positions | 52 | +25.12% | 7M | +14.64% |
| Decreased Positions | 95 | -45.89% | 9M | -20.34% |
| New Positions | 21 | New | 966,436 | New |
| Sold Out Positions | 38 | Sold Out | 4M | Sold Out |
| Total Postitions | 164 | -20.77% | 44M | -5.7% |
| Ra Capital Management, L.P. | $17,158.00 | 9.92% | 4.56M | -535,000 | -10.49% | 2024-12-31 |
| Blackrock, Inc. | $17,097.00 | 9.89% | 4.55M | -374,169 | -7.6% | 2025-03-31 |
| Goldman Sachs Group Inc | $16,074.00 | 9.29% | 4.27M | +683,943 | +19.05% | 2024-12-31 |
| Vr Adviser, Llc | $11,101.00 | 6.42% | 2.95M | -1M | -32.9% | 2024-12-31 |
| Vanguard Group Inc | $10,756.00 | 6.22% | 2.86M | +92,791 | +3.35% | 2024-12-31 |
| Bvf Inc/Il | $10,042.00 | 5.81% | 2.67M | -5M | -63.83% | 2024-12-31 |
| Janus Henderson Group Plc | $8,468.00 | 4.9% | 2.25M | -884,847 | -28.21% | 2024-12-31 |
| Morgan Stanley | $7,005.00 | 4.05% | 1.86M | +160,718 | +9.44% | 2024-12-31 |
| Novo Holdings A/S | $5,640.00 | 3.26% | 1.5M | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $5,342.00 | 3.09% | 1.42M | +1M | +1,607.07% | 2024-12-31 |